Vertex Pharmaceuticals (VRTX)
Health Care · $130B market cap · SEC CIK 0000875320
$514.99
▲+0.84% on the day
close of Sep 22, 2026
72
Screens strongly
fundamentals score out of 100
fundamentals score out of 100
Next reports on Nov 2, 2026, with analysts expecting $4.85 in earnings per share.
The case for VRTX
- Generated $3.2B of free cash flow in FY2025, 27% of revenue.
- 35% of revenue drops through to net profit.
- Revenue growing 10.2% year over year.
- Has compounded revenue at 14.1% a year over five years.
- Return on equity of 23%.
- Carries essentially no debt.
The case against
- Price/sales of 10.3× is higher than 93% of Health Care companies.
- Free-cash-flow yield of 2.5% is lower than 87% of Health Care companies.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 34 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 77 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 87 |
| Momentumhow the price has behaved lately | 77 |
| Stabilityhow violently it moves, what it owes and what it pays you | 91 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 29.5× |
|---|---|
| Price / book | 6.23× |
| Price / sales | 10.3× |
| Revenue growth (YoY) | +10.2% |
| EPS growth (YoY) | +22.5% |
| Gross margin | 86% |
| Operating margin | 38% |
| Net margin | 35% |
| Return on equity | 23% |
| Debt / equity | 0.00× |
| Current ratio | 3.19 |
| Dividend yield | none |
| Beta | 0.28 |
| 52-week range | $374.17 – $560.25 |
| Position in that range | 76% of the way up |
| 3-month return | +13.1% |
| 1-year return | +33.3% |
Five years of financials, as filed
Pulled from Vertex Pharmaceuticals's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B |
| Operating income | $4.2B | -$233M | $3.8B | $4.3B | $2.8B |
| Net income | $4.0B | -$536M | $3.6B | $3.3B | $2.3B |
| Operating cash flow | $3.6B | -$493M | $3.5B | $4.1B | $2.6B |
| Capital expenditure | $438M | $298M | $200M | $205M | $235M |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B |
| Total liabilities | $7.0B | $6.1B | $5.1B | $4.2B | $3.3B |
| Shareholder equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B |
| Cash | $5.1B | $4.6B | $10.4B | $10.5B | $6.8B |
| Free cash flow | $3.2B | -$790M | $3.3B | $3.9B | $2.4B |
| Operating margin | 34.8% | -2.1% | 38.8% | 48.2% | 36.7% |
| Net margin | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% |
| Diluted shares | 258M | 258M | 261M | 259M | 260M |
Share count is essentially flat over 4 years.
Risk factors VRTX lists in its 10-K
- Investing in our common stock involves a high degree of risk, and you should carefully consider the risks and
- uncertainties described below in addition to the other information included or incorporated by reference in this Annual
- Report on Form 10-K. If any of the following risks or uncertainties occur, our business, financial condition or results of
- operations would likely suffer, possibly materially. In that case, the trading price of our common stock could decline
- Risks Related to Our Business and Products
- Our success depends on our ability to develop and commercialize additional medicines
- Our business is substantially dependent on the success of our CF medicines
- If we are unable to successfully develop and commercialize medicines for acute and neuropathic pain, our business could
- We may not be able to increase or maintain CASGEVY product revenues
- We are subject to pricing and reimbursement pressures that could have a material adverse effect on our business,
- revenues, and results of operations
- Competing products and technological advances from our competitors may negatively affect our business and market
- If we discover safety or efficacy issues with any of our products, commercialization efforts for the product could be
- negatively affected, the approved product could lose its approval, and our business could be materially harmed